文献速递药物相互作用特殊人群用药

PSMA生物学临床视角:[177Lu]Lu-PSMA-617治疗前列腺癌的启示

PSMA Biology Through the Clinical Lens: Implications for Radioligand Therapy of Prostate Cancer with [177Lu]Lu-PSMA-617.
PubMed 文献 · Drugs · 2026-10-31

本文综述PSMA生物学特性及[177Lu]Lu-PSMA-617放射配体治疗mCRPC的临床证据。该药已在美国、英国和欧洲获批,TheraP、VISION和PSMAfore试验确立了其作用。无相关药物相互作用风险,可安全联用,但治疗后管理仍存挑战。

要点

  • PSMA在prostate cancer细胞高表达、正常组织低表达,支持精准靶向。
  • [177Lu]Lu-PSMA-617用于ARPI和紫杉类化疗后进展的mCRPC患者。
  • 该药无相关DDI风险,可与其他治疗联用,适合多药共用的虚弱患者。

核心结论

  • [177Lu]Lu-PSMA-617为ARPI和紫杉类化疗后进展的mCRPC患者提供有效治疗选择,已在美国、英国和欧洲获批。

研究设计与样本

  • 本文为综述,汇总PSMA生物学及[177Lu]Lu-PSMA-617从分子机制到临床应用的证据。

主要发现

  • PSMA是prostate cancer细胞高表达的跨膜糖蛋白,正常组织表达极低,支持选择性靶向并减少毒性。
  • [177Lu]Lu-PSMA-617由小分子配体PSMA-617与β发射同位素177Lu结合而成。
  • TheraP、VISION和PSMAfore等临床试验确立了[177Lu]Lu-PSMA-617在mCRPC中的角色。
  • 该药无相关药物相互作用风险,可安全考虑与其他治疗联用。

临床怎么用

  • 对ARPI和紫杉类化疗后进展的mCRPC患者,可考虑[177Lu]Lu-PSMA-617治疗。
  • 因无相关DDI风险,该药可与其他治疗联用,尤其适合多药共用的虚弱mCRPC患者。
  • 治疗后管理仍是挑战,需关注长期结局的优化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prostate cancer remains a leading cause of cancer-related mortality in men worldwide. While hormone therapy is effective in the early stages of advanced disease, multimodal approaches are often required as disease progresses, including radiotherapy, hormonal agents and chemotherapy. In metastatic castration-resistant prostate cancer (mCRPC), tumour cells become resistant to hormone therapy, resulting in poor survival outcomes despite systemic treatments. Among emerging therapies, radioligand therapy targeting prostate-specific membrane antigen (PSMA) has shown promise. PSMA is a transmembrane glycoprotein highly expressed in prostate cancer cells, with minimal expression in normal tissues. This selective distribution enables precision targeting and minimises toxicity. The radiotheranostic agent [177Lu]Lu-PSMA-617 combines PSMA-617, a small molecule ligand, with the beta-emitting radioisotope 177Lutetium. This therapy has demonstrated efficacy in patients with mCRPC who have progressed after androgen receptor pathway inhibitors and taxane-based chemotherapy. Its regulatory approval in the USA, UK and Europe marks a pivotal advancement in prostate cancer management. Clinical trials such as TheraP, VISION and PSMAfore have established the role of [177Lu]Lu-PSMA-617 in mCRPC and its potential additive effects with other anti-tumour therapies are under investigation. Strategies to enhance PSMA expression may further improve therapeutic response. With no relevant drug-drug interaction risk, [177Lu]Lu-PSMA-617 may be safely considered for use in combination with other therapies, a key advantage for frail patients with mCRPC on polypharmacy. Post-treatment management remains a challenge and ongoing research aims to optimise long-term outcomes. This review provides a comprehensive update on [177Lu]Lu-PSMA-617 therapy, from molecular mechanisms to clinical application and outlines future directions in the treatment of advanced prostate cancer.

来源:Drugs,查看原文。版权归原作者所有。

引用

  1. Del Re M, Bauckneht M, Danesi R, et al. PSMA Biology Through the Clinical Lens: Implications for Radioligand Therapy of Prostate Cancer with [177Lu]Lu-PSMA-617. Drugs. 2026. PMID: 42963536. doi:10.1007/s40265-026-02402-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。